INTRODUCTION:Until recently, therapy options for patients with acute myeloid leukemia (AML) were limited. This is changing due to advent of CLIA-approved next generation sequencing (NGS) panels and development of multiple new anti-leukemia agents. Examples are the recent approval of a FLT3and IDH2inhibitors. Multiple other targeted agents are currently being studied in clinical trials for AML. The aim of our study was to evaluate the impact of a NGS panel on the clinical practice at a major clinical trial research center. We report the experience in 1171 patients with AML who had a NGS panel evaluation as part of their clinical care during 2012-2015.